This book starts from the clinical reality, take practicality as the purpose, closely integrate clinical work, including important clinical therapeutic regimens for various cancer, and describes the new developments in treatment of common malignant tumors. At the same time, in combination with improved version of the ASCO value framework, systematic and standardized comparisons and in-depth evaluations of therapeutic regimens were made to promote the standardization of medical treatment decisions for malignant tumors. Compared with the traditional evaluation method of malignant tumor therapeutic regimens, the evaluation method of this book has outstanding advantages. First, the evaluation indicators are comprehensive and diverse. The evaluation includes multiple indicators such as clinical benefits, adverse reactions, additional benefits, and costs, and includes more effective evaluation indicators to comprehensively evaluate the treatment plan. Second, the evaluation indicators are converted into numerical values, and different indicators are effectively quantified to make the result evaluation easier and more objective. This book systematically and comprehensively reflects the highest level of diagnosis and treatment of common oncology from a new perspective. It has great clinical guidance value and will be a valuable reference book for clinicians, medical students, graduate students and related researchers.
Les mer
This book starts from the clinical reality, take practicality as the purpose, closely integrate clinical work, including important clinical therapeutic regimens for various cancer, and describes the new developments in treatment of common malignant tumors.
Les mer
Medicine in General Introduction.- Medicine in Brain Tumors.- Medicine in Head and Neck Tumors.- Medicine in Nasopharyngeal Cancer.- Medicine in Lung Cancer.- Medicine in Pleural Mesothelioma.- Medicine in Thymoma.- Medicine in Breast Cancer.- Medicine in Esophageal Cancer.- Medicine in Gastric Cancer.- Medicine in Liver Cancer.- Medicine in Biliary Tumors.- Medicine in Pancreatic Cancer.- Medicine in Pancreatic Neuroendocrine Tumors.- Medicine in Colorectal Cancer.- Medicine in Anal Canal Cancer.- Medicine in Gastrointestinal Stromal Tumor.- Medicine in Gynecological Tumors.- Medicine in Urinary System Tumors.- Medicine in Male Reproductive System Tumors.- Medicine in Melanoma.- Medicine in Osteosarcoma.- Medicine in Soft Tissue Sarcoma.- Medicine in Malignant Lymphoma.- Medicine in Multiple Myeloma.- Medicine in Unknown Primary Malignant Tumors.
Les mer
This book starts from the clinical reality, take practicality as the purpose, closely integrate clinical work, including important clinical therapeutic regimens for various cancer, and describes the new developments in treatment of common malignant tumors. At the same time, in combination with improved version of the ASCO value framework, systematic and standardized comparisons and in-depth evaluations of therapeutic regimens were made to promote the standardization of medical treatment decisions for malignant tumors.Compared with the traditional evaluation method of malignant tumor therapeutic regimens, the evaluation method of this book has outstanding advantages. First, the evaluation indicators are comprehensive and diverse. The evaluation includes multiple indicators such as clinical benefits, adverse reactions, additional benefits, and costs, and includes more effective evaluation indicators to comprehensively evaluate the treatment plan. Second, the evaluation indicatorsare converted into numerical values, and different indicators are effectively quantified to make the result evaluation easier and more objective.This book systematically and comprehensively reflects the highest level of diagnosis and treatment of common oncology from a new perspective. It has great clinical guidance value and will be a valuable reference book for clinicians, medical students, graduate students and related researchers.
Les mer
Comprehensively and systematically evaluates the treatment programs for malignant tumors The evaluation indicators are converted into numerical values Includes multiple indicators such as clinical benefits, adverse reactions, additional benefits, and costs
Les mer
GPSR Compliance The European Union's (EU) General Product Safety Regulation (GPSR) is a set of rules that requires consumer products to be safe and our obligations to ensure this. If you have any concerns about our products you can contact us on ProductSafety@springernature.com. In case Publisher is established outside the EU, the EU authorized representative is: Springer Nature Customer Service Center GmbH Europaplatz 3 69115 Heidelberg, Germany ProductSafety@springernature.com
Les mer

Produktdetaljer

ISBN
9789819914234
Publisert
2024-08-12
Utgiver
Vendor
Springer Verlag, Singapore
Høyde
279 mm
Bredde
210 mm
Aldersnivå
Professional/practitioner, P, 06
Språk
Product language
Engelsk
Format
Product format
Heftet

Om bidragsyterne

Editor Qiu Li is a professor at the Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.

Editor Xiao-Shi Zhang is a professor at the Biotherapy Center, Sun Yat-sen University Cancer Center, Guangzhou, China.